IL25 and asthma: This is the first study to provide evidence that a therapeutic anti-IL-25 mAb will directly boost airway epithelial cell anti-viral immunity and points to IL-25 blockade as being particularly beneficial for viral asthma exacerbations where a therapy with dual activity – block type 2 inflammation and promote anti-viral immunity – would be desirable.